

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 January 2005 (06.01.2005)

PCT

(10) International Publication Number  
**WO 2005/000300 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/427**,  
31/4192, 31/4196, 31/433, A61P 35/00, 31/12, 19/02,  
11/06, 3/10, 17/00, 25/00, 25/28, 37/00

(Cambridge) Limited, Granta Park, Abington, Cambridge  
CB1 6GB (GB).

(21) International Application Number:  
PCT/GB2004/002755

(74) Agent: **WALLS, Alan, James**; Vernalis (Cambridge)  
Limited, Granta Park, Abington, Cambridge CB1 6GB  
(GB).

(22) International Filing Date: 24 June 2004 (24.06.2004)

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0315111.5 27 June 2003 (27.06.2003) GB

(71) Applicants (*for all designated States except US*): **VER-  
NALIS (CAMBRIDGE) LIMITED** [GB/GB]; Granta  
Park, Abington, Cambridge CB1 6GB (GB). **CANCER  
RESEARCH TECHNOLOGY LTD.** [GB/GB]; 61  
Lincoln's Inn Fields, London WC2A 3PX (GB). **THE  
INSTITUTE OF CANCER RESEARCH** [GB/GB];  
Royal Cancer Hospital, 123 Old Brompton Road, London  
SW7 3RP (GB).

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **CHEUNG, Kwai,  
Ming** [CN/GB]; The Institute of Cancer Research, Royal  
Cancer Hospital, 123 Old Brompton Road, London  
SW7 3RP (GB). **DYMOCK, Brian, William** [GB/GB];  
Vernalis (Cambridge) Limited, Granta Park, Abington,  
Cambridge CB1 6GB (GB). **MACDONALD, Edward**  
[GB/GB]; The Institute of Cancer Research, Royal Cancer  
Hospital, 123 Old Brompton Road, London SW7 3RP  
(GB). **DRYSDALE, Martin, James** [GB/GB]; Vernalis

Published:

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: SUBSTITUTED 5-MEMBERED RING COMPOUNDS AND THEIR USE



(I)

(57) Abstract: Compound of a compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof, in the preparation of a composition for inhibition of HSP90 activity: wherein ring A is an aromatic or non-aromatic carbocyclic or heterocyclic ring having 5 ring atoms, for example 1,2,3-triazolyl or a 1,2,4-triazolyl or a tetrazolyl ring; and R<sub>1</sub> R<sub>2</sub> R<sub>3</sub> are as defined in the specification are inhibitors of HSP90 and therefore of use in the treatment of, for example, cancers, viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor; or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie /CJD, Huntingdon's and Alzheimer's disease.

WO 2005/000300 A1